Cited 0 times in
Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.